Pharmaceutical Pricing and Medical Innovation
Featured Topics
Lead story
Other featured articles
-
How Would Sharing Rebates at the Point-Of-Sale Affect Beneficiary Cost-Sharing in Medicare Part D?
If cost-sharing were based on net price it would provide meaningful financial relief to many Part D beneficiaries.
Posted in -
Health Technology Assessment for the U.S. Healthcare System
A white paper from the USC Schaeffer Center-Aspen Institute Advisory Panel on health technology assessment in the U.S. Experts explore how to better link the price of health technologies to the benefits they provide to patients while ensuring a sustainable healthcare ecosystem that supports innovation.
-
The Potential Benefits of Deferred Payment
Hlavka and his colleagues used a hypothetical gene therapy for congestive heart failure to assess the impact of a new payment model on access and outcomes.
-
The Association Between Drug Rebates and List Prices
Drug rebates and list prices are positively correlated: On average, a $1 increase in rebates is associated with a $1.17 increase in list price.
Posted in
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.
Our Experts On Pharmaceutical Pricing and Medical Innovation
Our Work In Pharmaceutical Pricing and Medical Innovation
-
Obesity, Second to Smoking as the Most Preventable Cause of US Deaths, Needs New Approaches
Nearly 40% of Americans are obese, and the numbers are climbing. The U.S. needs to get serious about solutions.
Categorized in -
Potential Impacts of Recreational Marijuana Policies and Regulatory Structures that Could Reduce its Negative Impacts
Rosalie Liccardo Pacula presented before the Florida House of Representatives Health & Human Services Committee, Subcommittee on Health Quality on Dec. 11, 2019 about regulations to govern the use of recreational marijuana.
-
It’s Hard to Lower Drug Prices, If You Don’t Know What They Are
In an op-ed for The Hill, Professor Neeraj Sood writes that until legislators and regulators understand where the profits are flowing in the prescription drug distribution system, bills to control prices risk being ineffective.
Categorized in -
CBO Estimate on Pelosi Drug Bill Misses its Long-Term Impact on Health
The CBO estimated that the Pelosi drug pricing reform legislation proposed would save Medicare $345 billion over seven years. It failed to look at the long-term effect on new drug discovery and the impact on population health.
Categorized in -
Accounting for Hope: Using ‘Mean Survival Gain’ to Price New Cancer Drugs
Outrage about the rising prices of prescription drugs has put cancer drugs in the spotlight. But there’s an important question that needs to be asked: What is the best metric to evaluate them?
Categorized in -
Expanding the Role of the Patient-Centered Outcomes Research Institute: Reauthorization and Facilitating Value Assessments
Should Congress reauthorize funding for the Patient-Centered Outcomes Research Institute (PCORI)? Professor William Padula writes the PCORI can generate research relevant for shifting to value-based healthcare.
Categorized in